Table 2.
Duration of eculizumab treatment and eculizumab treatment status (data for the safety analysis set, n = 71).
| Patients who received eculizumab, n (%) (Safety analysis set, n = 71) | |
|---|---|
| Overall eculizumab treatment duration, weeks | |
| Mean (SD) | 44.6 (23.7) |
| Median (range) | 52.1 (0.1–104.4) |
| Total eculizumab cumulative dose, mg | |
| Mean (SD) | 26,126 (13,393) |
| Median (range) | 31,114 (900–63,086) |
| Eculizumab treatment status, ongoing/discontinued, n (%) | |
| At week 26 | 62 (87.3)/9 (12.7) |
| At year 1 | 40 (56.3)/1 (1.4) |
| At year 2 | 4 (5.6)/2 (2.8) |
| At interim analysis data cut-off (1 April 2022) | 59 (83.1)/12 (16.9) |
| Reason for discontinuation | |
| Adverse event | 3 (4.2) |
| Death | 0 (0.0) |
| Lost to follow-up | 0 (0.0) |
| Physician decision | 6 (8.5) |
| Patient decision | 5 (7.0) |
| Relapse | 0 (0.0) |
| Symptomatic improvement | 0 (0.0) |
| Other | 1 (1.4) |
| Blank | 0 (0.0) |
SD, standard deviation.